e-learning
resources
Amsterdam 2011
Wednesday, 28.09.2011
Treating childhood asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal
M. Keller, O. Denk, A. Bucholski, M. Knoch (Graefelfing, Germany)
Source:
Annual Congress 2011 - Treating childhood asthma
Session:
Treating childhood asthma
Session type:
Poster Discussion
Number:
4829
Disease area:
Airway diseases, Paediatric lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Keller, O. Denk, A. Bucholski, M. Knoch (Graefelfing, Germany). Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal. Eur Respir J 2011; 38: Suppl. 55, 4829
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?
Source: Eur Respir J 2004; 24: 1-2
Year: 2004
Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes
Source: Virtual Congress 2021 – Wheezing illnesses along the life span
Year: 2021
Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011
Which therapeutic options when CPAP fails?
Source: ERS Course 2017 - Paediatric noninvasive ventilation
Year: 2017
Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
How to optimise the efficacy of pharmacological treatments?
Source: Annual Congress 2011 - New advances in smoking cessation
Year: 2011
Does combination therapy lead to better adherence in asthma?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Evaluating disease-modifying treatment in CF: are we ready to take the challenge?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014
Development and evaluation of an educational intervention targeted at optimising adherence with measures to prevent asthma in children with a familial allergic disposition (FOCUS-project)
Source: Eur Respir J 2002; 20: Suppl. 38, 329s
Year: 2002
When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma?
Source: Eur Respir J, 58 (3) 2100304; 10.1183/13993003.00304-2021
Year: 2021
Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer
Source: ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020
Year: 2021
How effective are oral steroids in asthma action plans?
Source: International Congress 2017 – Asthma management
Year: 2017
Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy?
Source: Eur Respir J 2006; 28: Suppl. 50, 319s
Year: 2006
Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003
Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
Source: Eur Respir Rev 2016; 25: 223-226
Year: 2016
A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006
Early detection of asthma exacerbations and the use of action points for treatment decisions in self-management plans
Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases
Year: 2011
Update on novel anticoagulants: indications, dosing alternatives and outcomes
Source: International Congress 2018 – Pulmonary embolism: what we need to know
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept